Abagovomab

Abagovomab
Monoclonal antibody
Type	Whole antibody
Source	Mouse
Target	(imitates CA-125)
Clinical data
Pregnancy; category	N/A;
Routes of; administration	subcutaneous
ATC code	none;
Pharmacokinetic data
Bioavailability	N/A
Excretion	N/A
Identifiers
CAS Number	792921-10-9 ;
ChemSpider	none;
UNII	3YK0326U7X;
	(what is this?) (verify)

Abagovomab is an investigational new drug that is being developed by the pharmaceutical company Menarini for the treatment of ovarian cancer.

Abagovomab is a mouse anti-idiotype monoclonal antibody whose variable epitope mimics the tumour-associated antigen CA-125, which is highly expressed in epithelial ovarian cancer. Unlike antibodies that directly target CA-125, abagovomab acts as a "surrogate" antigen. By mimicking CA-125, it prompts the immune system to recognize and attack tumour cells expressing this protein. It is hoped that this immune response will eliminate residual tumour cells and help prevent disease recurrence.^[1]

^ Berek J, Pfisterer J, Sabbatini P, Grisham RN (February 2011). "Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer". Immunotherapy. 3 (2): 153–162. doi:10.2217/imt.10.100. PMC 3221001. PMID 21322756.

[Berek_2011-1] Berek J, Pfisterer J, Sabbatini P, Grisham RN (February 2011). "Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer". Immunotherapy. 3 (2): 153–162. doi:10.2217/imt.10.100. PMC 3221001. PMID 21322756.

[1]